| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -10,550 | -6,150 | 1,350 | 1,230 | 0 |
| Net Income Growth | -71.54% | -555.56% | +9.76% | unch | unch |
Greenland Mines Ltd (GRML)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Greenland Mines Ltd operating divisions include Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland. Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. Greenland Mines Ltd, formerly known as Klotho Neurosciences Inc., is based in CHARLOTTE, N.C.
Fiscal Year End Date: 12/31